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Commentary on Taghavi et al. (2018): Accurate
measurement of tobacco smoke exposure and smoking
behaviour matters
In pregnancy, ‘total nicotine equivalents’ (TNE) and ‘total’
cotinine (TC) concentrations reﬂect nicotine (tobacco
smoke) exposure more accurately than the widely used
biomarker, ‘free’ cotinine. Although the number of cigarettes
smoked daily (CPD) is similarly a poor proxy for such
exposures, this measure can still be useful in population
surveys.
Taghavi and colleagues compare three measures of
smoking: self-reported smoking, urinary concentrations of
the nicotine biomarker cotinine and urinary concentra-
tions of ‘total nicotine equivalents’ (TNE), a more compre-
hensive measure of both nicotine and its metabolites. They
then use this comparison to assess the utility of each for
measuring nicotine exposure in pregnant women [1].
The TNE measure was used as a ‘gold standard’ against
which other measures were judged, because it reﬂects up
to 88% of nicotine intake [2] and is not inﬂuenced by
pregnancy-induced acceleration in the metabolism of
nicotine and cotinine [3]. Using the TNEmeasure, nicotine
exposure was similar in early and late pregnancy (approx-
imately 13 and 30 weeks) but much higher by approxi-
mately 25 weeks postpartum [1], presumably because
women who had stopped smoking in pregnancy re-started
smoking afterwards. Most nicotine is metabolized to
cotinine [4] so, unsurprisingly, free cotinine levels showed
a similar pattern; however, due to the faster metabolism
of cotinine in pregnancy [5,6], these levels were correlated
less strongly with TNE during gestation. Consequently, free
cotinine measurements would have underestimated
nicotine exposures by 55% in early and 65% in late
pregnancy. In contrast, total cotinine (free cotinine and
cotinine glucuronide combined) was correlated more
strongly with TNE, and this correlation remained consis-
tent during and after pregnancy and also in women with
faster and slower nicotine metabolisms, suggesting that
total cotinine levels reﬂect nicotine exposures as accurately
as do TNE levels.For women who smoke in pregnancy
and who do not use nicotine replacement therapy or
e-cigarettes, all nicotine exposure comes from tobacco
smoke and any measure which predicts nicotine intake
accurately also predicts heaviness of smoking and of
tobacco smoke toxin exposure. Accordingly, Taghavi
et al.’s ﬁndings have implications for how such exposures
might be validated in observational cohort studies investi-
gating fetal, infant and maternal harms from smoking in
pregnancy. Free cotinine (FC), a frequently used biomarker,
underestimates nicotine exposure. TNE and total cotinine
(TC) are the most accurate exposure biomarkers, and fu-
ture studies using either would minimize ‘noise’ incurred
during exposure measurement, maximizing the chances
of detecting valid associations between exposure in preg-
nancy and outcomes. Hitherto unidentiﬁed dose–response
relationships between smoking in pregnancy and adverse
outcomes might become apparent, and better quantiﬁca-
tion of known risks from smoking in pregnancy may be
possible. For example, using free cotinine, a biomarker
which Taghavi et al. show reﬂects nicotine less closely than
others, it has been shown recently that there is no ‘safe’
level of second-hand smoking, as children with the very
lowest detectable urinary free cotinine levels had poorer
asthma outcomes than those with no measurable urinary
free cotinine [7]. More sensitive quantiﬁcation of tobacco
smoke exposure in pregnancy using biomarkers such as
TNE and total cotinine could lead to other, novel insights,
potentially with substantial public health implications.
Due to discrepancies between numbers of cigarettes
smoked daily [cigarettes per day (CPD)] and TNE, Taghavi
et al. rightly question the use of CPD to measure nicotine
exposure [1]. In a smoking cessation trial such as theirs
[8], one might expect women who do not quit to report a
lower CPDwhen asked later in pregnancy. The authors cite
other reports of reducedCPD in late pregnancy, and suggest
that there is also bias against women admitting how
heavily they smoke operating in those studies. However,
in those survey studies such bias is probably less important,
as there is no expectation, apart from the usual societal
expectations, that participants should stop smoking during
pregnancy, whereas cessation trials generally recruit
women who are committed to stopping smoking. Hence,
trial participants may perceive greater pressure to report
changes in smoking behaviour at follow-up. Behavioural
surveys are generally cross-sectional [9] and, as some
participants are inevitably lost to follow-up, respondents
at baseline and follow-upmay not be the samewomen; bias
arising from such attrition could bemore inﬂuential. Tomy
knowledge, there is only one survey of pregnant women’s
smoking behaviour which has reported longitudinal CPD
data at different times in pregnancy and which adjusts
these for loss to follow-up [10]. This showed very similar
CPD levels in early and late pregnancy and also in the post-
partum period [10]. Another longitudinal study reported
movement between different categories of smoking heavi-
ness as pregnancy progressed but, similarly, did not reveal
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a trend towards lighter smoking in later pregnancy either
[11]. Perhaps the problem is less with the CPD measure it-
self and more a function of the design and analysis of
studies using it? CPDmay not be a great exposuremeasure,
but it is cheap and easily administered and very probably re-
mains a valid measure of smoking behaviour in pregnancy
provided that the biases inherent in collecting self-report
data on this socially undesirable habit are understood.
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